Fact CheckerSign in

NCT06396403Completed

The Role of Red Cell Characteristics, Angiogenesis, Viscosity and Oxygenation in the Pathophysiology of Sickle Cell Related Retinopathy

Source: ClinicalTrials.gov · Last updated 15 Nov 2024

Brief summary (registry, in English)

Objective: to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics. Endpoints: The investigators will determine the difference in the above named parameters between patients with and without PSCR Study design: This case control study will include adult sickle cell disease patients with the HbSS or HbSC genotype. For both genotypes, 20 patients without sickle cell retinopathy (SCR) and 20 patients with PSCR will be included, resulting in a total of 80 patients. Venous blood samples and retinal imaging scans will be collected for each included patient.

Status (registry)
Completed
Study type
Observational
Enrollment
68 (actual)
First submitted
24 Apr 2024
Start date
13 Jun 2023
Primary completion date
17 Jun 2024
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT number
NCT06396403

What you commit to

  • Study type: Observational
  • Participants enrolled: 68
  • From 13 Jun 2023 to the primary completion date, 17 Jun 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age

  • Age below 18 years

Other

  • Genotype other than HbSC or HbSS
  • No recent ophthalmologic examination and no intention to visit the outpatient clinic for ophthalmic and hematologic examination
  • Participation in trials with either crizanlizumab, voxelotor or mitapivat.

Who the study is looking for

  • Minimum age of 18 years
  • HbSC or HbSS genotype
  • Recent ophthalmologic examination (up to 2 years prior) or (willingness to attend) upcoming examination

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Amsterdam UMC
Coordinator of this site? Confirm its status
AmsterdamNetherlandsUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.